<DOC>
	<DOCNO>NCT00765050</DOCNO>
	<brief_summary>The primary objective analyze safety efficacy CD133+ cell , obtain peripheral blood treatment diabetic patient critic ischemia low limb . The secondary objective : - To determine safety intramuscular administration CD133+ cell mobilize peripheral blood . - To determine CD133+ capacity increase re-vascularization lower limbs diabetic patient critic ischemia low limb . - To evaluate patient global health condition use notified result SF-36 questionnaire complete patient</brief_summary>
	<brief_title>A Prospective , Open , Non-randomized Phase I/II Study Therapeutic Angiogenesis Diabetic Patients With Critic Ischemia Lower Limbs While Administering Positive CD133 Mobilized With G-CSF</brief_title>
	<detailed_description>A total 20 diabetic patient critic ischemia low limb include study . Patients administer CD133+ cell , previously obtain peripheral blood mobilization G-CSF The study divide three phase : Pre-treatment ( previous 4 week CD133+ cell mobilization ) . Treatment ( cell mobilization , CD133+ transplant , 24 hour infusion visit , 4 , 12 24 week transplant visit ) Follow-up ( 9 12 month transplant visit )</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<criteria>According investigator opinion , patient able carry clinical trial requirement Patient must volunteer sign inform consent study specific test , part common patient attention , perform . Patient must know he/she abandon study time damage his/her posterior attention Age 18 75 A diagnosis chronic critic ischemia lower limb Diabetes Mellitus active III IV stage ( Fontaine classification ) : resting pain , ulcer minor gangrene major amputation General contraindication local inoperability refractory/progression previous surgical treatment , accord investigator criterion If female reproductive potential , negative pregnancy test Pregnant currently breast feed woman Acute myocardial infarction within last 3 year Non revascular unstable angina pectoris History ischemia stroke within last 3 year Neoplasia time inclusion Chemotherapy Radiotherapy treatment last 5 year Chronic renal insufficiency GCSF contraindication A non well control serious concomitant disease History serious thrombotic episode within past 3 year Patients receive investigational therapy within 30 day previous study inclusion Patients currently clinical trial receive investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Cellular therapy</keyword>
	<keyword>CD133+</keyword>
</DOC>